Claris Lifesciences rose 7.88% to Rs 236.90 at 15:30 IST on BSE after Reliance Mutual Fund bought 1.15% stake in the company through bulk deal on BSE on Thursday, 1 October 2015.
Meanwhile, the BSE Sensex was up 583.29 points, or 2.22%, to 26,804.24.
On BSE, so far 5.13 lakh shares were traded in the counter, compared with an average volume of 1.19 lakh shares in the past one quarter.
The stock hit a high of Rs 239.80 and a low of Rs 225.80 so far during the day. The stock hit a record high of Rs 358 on 13 April 2015. The stock hit a 52-week low of Rs 163.10 on 22 October 2014.
The stock had outperformed the market over the past one month till 1 October 2015, rising 12.44% compared with 2.04% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, sliding 7.77% as against Sensex's 6.42% decline.
The small-cap company has an equity capital of Rs 54.57 crore. Face value per share is Rs 10.
On Thursday, 1 October 2015, Reliance Mutual Fund (Reliance MF) acquired 6.25 lakh shares, or 1.15% stake, of Claris Lifesciences at Rs 201 on BSE. Shares were purchased from Barclays Capital Mauritius, which sold 7.70 lakh shares of the Indian company at Rs 201.28 on BSE.
On a consolidated basis, net profit of Claris Lifesciences rose 31.07% to Rs 20.29 crore on 23.48% rise in net sales to Rs 186.51 crore in the quarter ended June 2015 over the quarter ended June 2014.
Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly-owned subsidiary dealing in specialty injectables business, collectively "Claris"; and "Claris Otsuka", a joint venture with Japanese Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. for infusion business in India and emerging markets.
Powered by Capital Market - Live News
